This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

BRCA1 and BRCA2 and pancreatic cancer

Authoring team

BRCA1/2 and pancreatic cancer

  • Familial pancreatic cancer (FPC) includes those kindreds that contain at least two first degree relatives with pancreatic ductal adenocarcinoma
    • has been suggested that about 10% of pancreatic cancer has a familial basis (1)

  • BRCA1 and BRCA2 gene are well-known high-penetrant predisposing genes for hereditary breast and/or ovarian cancer (HBOC) (2)
    • these genes are involved in the DNA damage response and DNA double-strand breaks repair
  • pancreatic cancer is the third most common cancer associated with BRCA1/2 mutations, though the penetrance at age 70 is much lower (3)
    • prevalence of BRCA2 mutations in pancreatic cancer patients is 1.4-8.2% for patients unselected for family history, about 6-16% among familal pancreatic cancer patients, and up to 17.2% in families with 3 or more pancreatic cancers (3)
      • germline (inherited) mutations in the BRCA2 gene increase the risk of breast and ovarian cancer, and increase the risk of pancreatic cancer 3.5 to 10-fold
        • while breast cancer develops in most families with a BRCA2 gene mutation, the absence of a breast cancer in a family should not be used to exclude germline BRCA2 mutations
          • pancreatic cancer can run in BRCA2 gene mutation-carrying families without an apparent association with breast cancer
        • germline BRCA2 mutations are particularly common in individuals of Ashkenazi Jewish heritage
          • has been calculated that 1% of the Ashkenazi Jewish population carries a germline BRCA2 gene mutation, the 6174delT mutation, and these individuals, in addition to an increased risk of breast and ovarian cancer, have a 10-fold increased risk of developing pancreatic cancer (1)
    • comparing to the general population, the risk of pancreatic cancer is about 2-6 fold in BRCA2 carriers and 2-5 fold in BRCA1 carriers (3)

Reference:

  • Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg. 2010;44:293-311. doi:10.1016/j.yasu.2010.05.011
  • Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43(5):548-553. doi:10.1053/j.seminoncol.2016.09.002
  • Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017;6(6):58. doi:10.21037/cco.2017.12.04

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.